eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. is the de-SPAC successor to Locust Walk Acquisition Corp (LWAC), a blank-check company sponsored by Locust Walk Partners that completed its initial public offering in 2021 targeting the life sciences sector. The business combination between LWAC and eFFECTOR Therapeutics, a clinical-stage biopharmaceutical company developing oncology-focused translation regulator inhibitors, closed in August 2021, with the combined entity subsequently trading under the ticker EFTR on Nasdaq. The Form 8-K filed February 24, 2022 represents a corporate disclosure from the post-merger operating period. For complete filing history, deal metrics, and ownership data on LWAC and its successor entity, sign up for full access at SpacDesk.